This study is in progress, not accepting new patients
A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy
Summary
- Eligibility
- for people ages 18 months to 10 years (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Retrotope, Inc.
- ID
- NCT03570931
- Phase
- Phase 2/3 Infantile Neuroaxonal Dystrophy Research Study
- Study Type
- Interventional
- Participants
- About 19 people participating
- Last Updated